The Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA) have launched the SMART Antiviral Prize, a multi-stage, $100+ million initiative designed to close critical gaps in the national therapeutic pipeline. Focused on developing novel, broad-spectrum, small-molecule antivirals, the program explicitly targets high-consequence pathogens capable of causing severe morbidity and mortality.
For innovators navigating the SMART Antiviral framework—from the initial Concept Stage through Stage 1 (Hit-to-Lead), Stage 2 (Lead Optimization), and ultimately Stage 3 & 4 (In-vivo validation and IND Readiness)—success relies on generating robust, reproducible preclinical data. Securing early “go/no-go” datasets and advancing towards Investigational New Drug (IND) submission requires an accelerated, highly specialized testing infrastructure backed by an experienced CRO partner.
To establish a versatile Medical Countermeasure (MCM) ecosystem, ASPR and BARDA require therapeutic candidates to demonstrate efficacy against a diverse panel of Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) priority viral families. The pathogens prioritized for MCM platform validation present distinct transmission routes and complex clinical syndromes that must be addressed during therapeutic development:
Pathogens such as Dengue Virus (DENV) and West Nile Virus (WNV) are primarily mosquito-borne, driving severe hemorrhagic and neurologic syndromes.
Mosquito-borne viruses like Chikungunya (CHIKV) present with debilitating arthritogenic conditions
The priority list also encompasses Arenaviridae (Lassa Fever Virus; LASV), Paramyxoviridae (Nipah Virus; NiV), and Coronaviridae (MERS-CoV). These families cause severe pulmonary, neurologic, and hemorrhagic diseases, often with respiratory transmission potential.
BARDA’s framework also includes limited H2H pathogens like Andes Virus (ANDV) and tick-borne threats such as Crimean-Congo Hemorrhagic Fever Virus (CCHFV).
The overarching goal of the SMART campaign is to establish broad-spectrum platforms capable of rapidly adapting to unknown, future emergent viruses (Threat X).
Aligning with the rigorous milestone requirements of the SMART Antiviral Prize, IBT Bioservices provides a comprehensive, milestone-driven preclinical pathway. Our established infrastructure allows sponsors to seamlessly transition from early hit validation to definitive IND-enabling evaluations.
1. Target Characterization & Assay Development: The foundation of a successful broad-spectrum application is proving reproducible cell-based antiviral activity across multiple viral species.
2. Lead Optimization & Platform Validation: Stage 1 of the SMART program requires developers to identify a promising chemical series and build a robust “go/no-go” dataset.
3. Broad-Panel Evaluation & In Vivo Efficacy: Validating a true broad-spectrum antiviral requires comprehensive evaluation across a wide panel of viral families before culminating in definitive in vivo proof of concept for Phase I clinical trials.
3. Candidate Selection & IND-Enabling Studies: To culminate the SMART program journey, candidates must complete rigorous safety and toxicology profiling suitable for FDA regulatory review. All in vivo evaluations are supported by our dedicated infrastructure designed for strict regulatory compliance
The accelerated timeline and demanding scientific criteria of the BARDA SMART Antiviral Prize require a preclinical partner with deep infectious disease expertise and an established assay infrastructure. By providing validated models, specialized reagents, and comprehensive IND-enabling services, IBT Bioservices de-risks the development pathway for broad-spectrum therapeutics.
Beyond our scientific capabilities, we understand the unique operational demands of government-funded initiatives. When you partner with us, your program is supported by a dedicated Project Manager (PM) to ensure seamless execution and keep your deliverables strictly on time. We can facilitate consistent bi-monthly calls to maintain transparent communication and agile decision-making. Furthermore, our team brings proven, hands-on experience navigating complex BARDA reporting, milestone tracking, and billing requirements—alleviating the administrative burden so your team can focus entirely on advancing the science.
To discuss how IBT Bioservices can accelerate your MCM platform, seamlessly integrate with your SMART Antiviral application, and structure your preclinical roadmap, contact us today!
Partner with IBT Bioservices to de-risk your antiviral development and validate your medical countermeasure platforms. Our team is ready to help you customize a milestone-driven study design that meets strict ASPR and BARDA requirements.
